Starck Lea, Skeie Bente Sandvei, Moen Gunnar, Grüner Renate
Department of Physics and Technology, University of Bergen, Bergen, Norway.
Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
Neurooncol Adv. 2022 May 13;4(1):vdac070. doi: 10.1093/noajnl/vdac070. eCollection 2022 Jan-Dec.
Following stereotactic radiosurgery (SRS), predicting treatment response is not possible at an early stage using structural imaging alone. Hence, the current study aims at investigating whether dynamic susceptibility contrast (DSC)-MRI estimated prior to SRS can provide predictive biomarkers in response to SRS treatment and characterize vascular characteristics of pseudo-progression.
In this retrospective study, perfusion-weighted DSC-MRI image data acquired with a temporal resolution of 1.45 seconds were collected from 41 patients suffering from brain metastases. Outcome was defined based on lesion volume changes in time (determined on structural images) or death. Motion correction and manual lesion delineation were performed prior to semi-automated, voxel-wise perfusion analysis. Statistical testing was performed using linear regression and a significance threshold at = .05. Age, sex, primary cancers (pulmonary cancer and melanoma), lesion volume, and dichotomized survival time were added as covariates in the linear regression models (ANOVA).
Relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF) were found to be significantly lower prior to SRS treatment in patients with increasing lesion volume or early death post-SRS ( ≤ .01).
Unfavorable treatment outcome may be linked to low perfusion prior to SRS. Pseudo-progression may be preceded by a transient rCBF increase post-SRS. However, results should be verified in different or larger patient material.
立体定向放射外科治疗(SRS)后,仅使用结构成像在早期阶段无法预测治疗反应。因此,本研究旨在调查SRS前估计的动态磁敏感对比(DSC)-MRI是否能提供预测SRS治疗反应的生物标志物,并表征假性进展的血管特征。
在这项回顾性研究中,收集了41例脑转移瘤患者以1.45秒的时间分辨率采集的灌注加权DSC-MRI图像数据。结局根据病变体积随时间的变化(通过结构图像确定)或死亡来定义。在进行半自动体素灌注分析之前,先进行运动校正和手动病变勾勒。使用线性回归和显著性阈值α = 0.05进行统计检验。年龄、性别、原发癌(肺癌和黑色素瘤)、病变体积和二分法生存时间作为协变量纳入线性回归模型(方差分析)。
发现SRS治疗前,病变体积增加或SRS后早期死亡(≤0.01)的患者相对脑血容量(rCBV)和相对脑血流量(rCBF)显著降低。
不良治疗结局可能与SRS前的低灌注有关。假性进展可能在SRS后出现短暂的rCBF增加之前发生。然而,结果应在不同或更大的患者群体中得到验证。